650 related articles for article (PubMed ID: 28536452)
21. TRAIL and cancer therapy.
Kruyt FA
Cancer Lett; 2008 May; 263(1):14-25. PubMed ID: 18329793
[TBL] [Abstract][Full Text] [Related]
22. TNF-related apoptosis-inducing ligand: signalling of a 'smart' molecule.
Manzo F; Nebbioso A; Miceli M; Conte M; De Bellis F; Carafa V; Franci G; Tambaro FP; Altucci L
Int J Biochem Cell Biol; 2009 Mar; 41(3):460-6. PubMed ID: 18243765
[TBL] [Abstract][Full Text] [Related]
23. TRAIL receptor signaling and therapeutics.
Abdulghani J; El-Deiry WS
Expert Opin Ther Targets; 2010 Oct; 14(10):1091-108. PubMed ID: 20819019
[TBL] [Abstract][Full Text] [Related]
24. RAD001 (everolimus) enhances TRAIL cytotoxicity in human leukemic Jurkat T cells by upregulating DR5.
Lee MW; Kim DS; Eom JE; Ko YJ; Sung KW; Koo HH; Yoo KH
Biochem Biophys Res Commun; 2015 Aug; 463(4):894-9. PubMed ID: 26074143
[TBL] [Abstract][Full Text] [Related]
25. Down-regulation of intracellular anti-apoptotic proteins, particularly c-FLIP by therapeutic agents; the novel view to overcome resistance to TRAIL.
Hassanzadeh A; Farshdousti Hagh M; Alivand MR; Akbari AAM; Shams Asenjan K; Saraei R; Solali S
J Cell Physiol; 2018 Oct; 233(10):6470-6485. PubMed ID: 29741767
[TBL] [Abstract][Full Text] [Related]
26. Should We Keep Walking along the Trail for Pancreatic Cancer Treatment? Revisiting TNF-Related Apoptosis-Inducing Ligand for Anticancer Therapy.
Kretz AL; von Karstedt S; Hillenbrand A; Henne-Bruns D; Knippschild U; Trauzold A; Lemke J
Cancers (Basel); 2018 Mar; 10(3):. PubMed ID: 29562636
[TBL] [Abstract][Full Text] [Related]
27. Two death-inducing human TRAIL receptors to target in cancer: similar or distinct regulation and function?
van Roosmalen IA; Quax WJ; Kruyt FA
Biochem Pharmacol; 2014 Oct; 91(4):447-56. PubMed ID: 25150214
[TBL] [Abstract][Full Text] [Related]
28. Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio.
Mühlethaler-Mottet A; Flahaut M; Bourloud KB; Auderset K; Meier R; Joseph JM; Gross N
BMC Cancer; 2006 Aug; 6():214. PubMed ID: 16930472
[TBL] [Abstract][Full Text] [Related]
29. Natural Product Mediated Regulation of Death Receptors and Intracellular Machinery: Fresh from the Pipeline about TRAIL-Mediated Signaling and Natural TRAIL Sensitizers.
Shahwar D; Iqbal MJ; Nisa MU; Todorovska M; Attar R; Sabitaliyevich UY; Farooqi AA; Ahmad A; Xu B
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31022877
[TBL] [Abstract][Full Text] [Related]
30. TRAIL: a multifunctional cytokine.
Schaefer U; Voloshanenko O; Willen D; Walczak H
Front Biosci; 2007 May; 12():3813-24. PubMed ID: 17485341
[TBL] [Abstract][Full Text] [Related]
31. The TRAIL to cancer therapy: Hindrances and potential solutions.
Wong SHM; Kong WY; Fang CM; Loh HS; Chuah LH; Abdullah S; Ngai SC
Crit Rev Oncol Hematol; 2019 Nov; 143():81-94. PubMed ID: 31561055
[TBL] [Abstract][Full Text] [Related]
32. A human scFv antibody against TRAIL receptor 2 induces autophagic cell death in both TRAIL-sensitive and TRAIL-resistant cancer cells.
Park KJ; Lee SH; Kim TI; Lee HW; Lee CH; Kim EH; Jang JY; Choi KS; Kwon MH; Kim YS
Cancer Res; 2007 Aug; 67(15):7327-34. PubMed ID: 17671202
[TBL] [Abstract][Full Text] [Related]
33. Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand.
Mitsiades N; Poulaki V; Tseleni-Balafouta S; Koutras DA; Stamenkovic I
Cancer Res; 2000 Aug; 60(15):4122-9. PubMed ID: 10945619
[TBL] [Abstract][Full Text] [Related]
34. Hyperthermia enhances tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in human cancer cells.
Yoo J; Kim HR; Lee YJ
Int J Hyperthermia; 2006 Dec; 22(8):713-28. PubMed ID: 17391000
[TBL] [Abstract][Full Text] [Related]
35. Playing the DISC: turning on TRAIL death receptor-mediated apoptosis in cancer.
Pennarun B; Meijer A; de Vries EG; Kleibeuker JH; Kruyt F; de Jong S
Biochim Biophys Acta; 2010 Apr; 1805(2):123-40. PubMed ID: 19961901
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic targeting of CD95 and the TRAIL death receptors.
Gerspach J; Pfizenmaier K; Wajant H
Recent Pat Anticancer Drug Discov; 2011 Sep; 6(3):294-310. PubMed ID: 21762072
[TBL] [Abstract][Full Text] [Related]
37. Activation of KIT modulates the function of tumor necrosis factor-related apoptosis-inducing ligand receptor (TRAIL-R) in mast cells.
Förster A; Grotha SP; Seeger JM; Rabenhorst A; Gehring M; Raap U; Létard S; Dubreuil P; Kashkar H; Walczak H; Roers A; Hartmann K
Allergy; 2015 Jul; 70(7):764-74. PubMed ID: 25833810
[TBL] [Abstract][Full Text] [Related]
38. The death receptor DR5 is involved in TRAIL-mediated human osteoclast apoptosis.
Colucci S; Brunetti G; Cantatore FP; Oranger A; Mori G; Pignataro P; Tamma R; Grassi FR; Zallone A; Grano M
Apoptosis; 2007 Sep; 12(9):1623-32. PubMed ID: 17558561
[TBL] [Abstract][Full Text] [Related]
39. Tumor necrosis factor-related apoptosis-inducing ligand promotes migration of human bone marrow multipotent stromal cells.
Secchiero P; Melloni E; Corallini F; Beltrami AP; Alviano F; Milani D; D'Aurizio F; di Iasio MG; Cesselli D; Bagnara GP; Zauli G
Stem Cells; 2008 Nov; 26(11):2955-63. PubMed ID: 18772312
[TBL] [Abstract][Full Text] [Related]
40. TRAIL as a target in anti-cancer therapy.
Wu GS
Cancer Lett; 2009 Nov; 285(1):1-5. PubMed ID: 19299078
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
